PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-90.13%
Negative revenue growth while Healthcare median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-148.93%
Negative gross profit growth while Healthcare median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
-24.41%
Negative EBIT growth while Healthcare median is -4.60%. Seth Klarman would check if external or internal factors caused the decline.
-24.41%
Negative operating income growth while Healthcare median is -5.59%. Seth Klarman would check if structural or cyclical issues are at play.
-24.71%
Negative net income growth while Healthcare median is -5.07%. Seth Klarman would investigate factors dragging net income down.
-23.33%
Negative EPS growth while Healthcare median is -1.45%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-23.33%
Negative diluted EPS growth while Healthcare median is -0.47%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.59%
OCF growth of 9.59% while Healthcare is zero. Walter Schloss might see a modest positive difference, which can compound over time.
10.68%
FCF growth of 10.68% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1874.89%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
89.77%
OCF/share CAGR of 89.77% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
79.09%
3Y OCF/share growth of 79.09% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-5123.81%
Negative 10Y net income/share CAGR vs. Healthcare median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
89.73%
Net income/share CAGR of 89.73% while Healthcare median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
77.51%
3Y net income/share CAGR of 77.51% while Healthcare median is zero. Walter Schloss might see a small advantage that can be scaled further.
1605.51%
Equity/share CAGR exceeding 1.5x Healthcare median of 58.81% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
-64.94%
Negative 5Y equity/share growth while Healthcare median is 31.93%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
48.08%
3Y equity/share CAGR > 1.5x Healthcare median of 15.79%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.84%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-8.40%
Negative BV/share change while Healthcare median is 0.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-26.37%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
15.04%
R&D growth of 15.04% while Healthcare median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
33.15%
SG&A growth far above Healthcare median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.